Skip to content
  • Latest News
  • Advertising Policy
  • Contact Us
  • Cookie Policy
  • Privacy Policy
  • Terms and Conditions
  • About Us
Archyde

Archyde

  • News
  • World
  • Economy
  • Technology
  • Health
  • Entertainment
  • Sport

ARROS-1 phase I/II trial

FDA Approves GSK Jideytro for ROS1-Positive Non-Small Cell Lung Cancer

FDA Approves GSK Jideytro for ROS1-Positive Non-Small Cell Lung Cancer

September 15, 2026 by Dr. Priya Deshmukh - Senior Editor, Health

The U.S.

Categories Health Tags ARROS-1 phase I/II trial, Food and Drug Administration, GSK plc, Jideytro, Nuvalent Inc, Real-Time Oncology Review, ROS1-positive non-small cell lung cancer Leave a comment

Recent Posts

  • Teqball arrives at Asian Games with Olympic ambitions
  • FDA Approves GSK Jideytro for ROS1-Positive Non-Small Cell Lung Cancer
  • The 15 Best 21st-Century Sci-Fi TV Shows, Ranked
  • Bavaria Sees Rise in Primary Students Despite Rural School Decline
  • Capoeira Music & Movement Workshop: Sept 26 at The Chapel
  • Latest News
  • Advertising Policy
  • Contact Us
  • Cookie Policy
  • Privacy Policy
  • Terms and Conditions
  • About Us
© 2026 Archyde — All Rights Reserved. Contact | Privacy Policy